Breaking News Instant updates and real-time market news.

MU

Micron

$52.96

(0.00%)

, FCX

Freeport McMoRan

$13.12

0.175 (1.35%)

10:08
12/17/19
12/17
10:08
12/17/19
10:08

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) upgraded to Outperform from Neutral at Wedbush with analyst Matt Bryson saying the upgrade is not a call on the quarter, as he doesn't expect meaningful upside to Q1 and expects the company's Q2 outlook to also be muted or in-line with the Street, but that he sees an improving memory dynamic. 2. Freeport McMoRan (FCX) upgraded to Outperform from Market Perform at BMO Capital with analyst David Gagliano saying Freeport shares are positioned to be the "go to" name within the U.S. Metals & Mining sector for those seeking exposure to a broader macro-economic demand recovery in 2020. 3. Parker-Hannifin (PH) was upgraded to Buy from Neutral at BofA/Merrill and to Buy from Hold at Stifel. 4. Vera Bradley (VRA) upgraded to Outperform from Market Perform at Cowen with analyst Oliver Chen saying he believes performance and "hands free" driven product innovation will drive consistent comps. 5. Johnson & Johnson (JNJ) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Lewis saying pharma growth is likely to accelerate in 2020, which historically has lifted the stock's multiple, while its Consumer segment is stabilizing and the Medical Devices & Diagnostics unit has seen "six consecutive quarters of momentum improvement." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MU

Micron

$52.96

(0.00%)

FCX

Freeport McMoRan

$13.12

0.175 (1.35%)

PH

Parker-Hannifin

$209.22

1.61 (0.78%)

VRA

Vera Bradley

$11.53

0.45 (4.06%)

JNJ

Johnson & Johnson

$142.64

0.88 (0.62%)

  • 18

    Dec

  • 19

    Dec

  • 07

    Jan

  • 16

    Jan

  • 22

    Jan

MU Micron
$52.96

(0.00%)

12/17/19
WEDB
12/17/19
UPGRADE
Target $65
WEDB
Outperform
Micron upgraded to Outperform on improving memory dynamic at Wedbush
Wedbush analyst Matt Bryson upgraded Micron to Outperform from Neutral with a price target of $65, up from $44. In a research note to investors, Bryson says the upgrade is not a call on the quarter, as he doesn't expect meaningful upside to Q1 and expects the company's Q2 outlook to also be muted or in-line with the Street, but that he sees an improving memory dynamic. Specifically, Bryson says NAND pricing, SSDs in particular, should inflect upwards in Q1, adding that he believes periods of positive pricing change are the best periods to own memory stocks. He also says he expects demand for both NAND and DRAM to accelerate throughout 2020.
12/17/19
RBCM
12/17/19
NO CHANGE
Target $55
RBCM
Outperform
RBC Capital remains positive on Micron on expected DRAM price bounce
RBC Capital analyst Mitch Steves keeps his Outperform rating and $55 price target on Micron ahead of its Q1 earnings this week, cutting his FY20 EPS view to $3.02 from $3.48 but maintaining a positive stance on the stock on expectation that DRAM prices will improve. The analyst contends that earnings estimates on Micron will come down due to aggressive inventory de-stocking, but he believes that memory stocks will "work higher from here" with pricing now "past the bottom."
12/17/19
NEED
12/17/19
NO CHANGE
Target $70
NEED
Buy
Micron price target raised to $70 from $60 at Needham
Needham analyst Rajvindra Gill raised his price target on Micron to $70 and kept his Buy rating ahead of its Q1 earnings tomorrow, saying he expects a Q2 bottom for NAND and DRAM pricing as well as a mid-cycle recovery in 2020. The analyst adds that a "significant rebound" in memory pricing will be driven by multiple catalysts that include 5G smartphones, a rebound in hyperscaler spending, and normalized supply/demand. Gill is also raising his FY21 EPS view on Micron to $1.58 from $1.15.
12/17/19
WEDB
12/17/19
UPGRADE
WEDB
Outperform
Micron upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Micron to Outperform from Neutral.
FCX Freeport McMoRan
$13.12

0.175 (1.35%)

12/17/19
BMOC
12/17/19
UPGRADE
Target $17
BMOC
Outperform
Freeport McMoRan upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst David Gagliano upgraded Freeport McMoRan to Outperform from Market Perform with a price target of $17, up from $12. The shares closed Monday up 8c to $12.95. Freeport shares are positioned to be the "go to" name within the U.S. Metals & Mining sector for those seeking exposure to a broader macro-economic demand recovery in 2020, Gagliano tells investors in a research note. The company's risks for 2020 have diminished as the transition from surface to underground at Grasberg continues to progress ahead of schedule, adds the analyst. Further, he believes lowered copper price forecasts and the associated Freeport estimate reductions have shifted the forward-looking estimate revision potential from downward revision risk to upward revision.
12/11/19
JEFF
12/11/19
NO CHANGE
JEFF
Jefferies ups Vale, downgrades Antofagasta in metals & mining rating shuffle
As previously reported, Jefferies analyst Christopher Lafemina upgraded Vale (VALE) to Buy from Hold with a $16 price target, up from $13, and downgraded Antofagasta (ANFGY) to Hold from Buy with a price target of 950 GBp, down from 1,050 GBp, as part of a broader sector note on metals & mining. In speaking about the sector as a whole, Lafemina said he expects miners to benefit from ongoing strength in iron ore and the beginning of a cyclical recovery in copper and other industrial commodities in 2020. On Vale specifically, he cited his "stronger for longer" iron ore view, as well as valuation and what he sees as operational upside. While he expect Antofagasta to benefit from his bullish view on copper prices, Lafemina sees capex risk along with geopolitical risk in Chile, leading him to view the shares as fairly valued at the current price when compared to Freeport McMoRan (FCX) and First Quantum Minerals (FQVLF), which trade at discounts to their net present values.
11/15/19
SBSH
11/15/19
NO CHANGE
SBSH
Citi makes Freeport McMoRan top pick in copper, says 'risk-on' winner
Citi's global commodity team highlights copper as their top pick for 2020, analyst Alexander Hacking tells investors in a research note. The analyst says this makes sense given the upside potential if global trade tensions are eased along with cooper's "superior" supply/demand dynamics relative to other base metals. Hacking shifted his top pick to Freeport McMoRan (FCX), which he says offers more leverage to upside in copper. The stock is arguably the most "risk on" exposed stock in Americas mining given its liquidity and beta, Hacking tells investors in a research note. The analyst believes the "gradual de-risking" of Grasberg "appears to be mostly ignored by the market so far." In addition, Southern Copper (SCCO) has been an outperformer year-to-date and "remains a relatively safer, lower beta play," contends Hacking.
11/13/19
11/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. G-III Apparel (GIII) upgraded to Buy from Neutral at BofA/Merrill with analyst Heather Balsky saying she anticipates the company to benefit from a likely accelerated wind-down of unprofitable outlet business and derisking with regards to tariffs. 2. Rockwell Automation (ROK) upgraded to Neutral from Underperform at Credit Suisse with analyst John Walsh saying he is upgrading shares based on his view that Industrial Production recovers in 2H20, achievable EPS growth in FY20 driven by restructuring on flat organic sales and a more balanced risk/reward valuation profile. 3. Infinera (INFN) upgraded to Neutral from Underweight at JPMorgan with analyst Samik Chatterjee saying she believes Infinera's recent Coriant acquisition execution is going to make investors more willing to "position themselves for the upside" from the company achieving profitability metrics similar to larger competitor Ciena (CIEN). 4. Freeport McMoRan (FCX) upgraded to Buy from Neutral at BofA/Merrill with analyst Timna Tanners saying she is looking past the company's "transition year" and expects its Grasberg asset to make a full contribution for copper and gold production. 5. Five9 (FIVN) upgraded to Buy from Neutral at Rosenblatt with analyst Ryan Koontz saying he came away from the company's analyst event "thoroughly impressed." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PH Parker-Hannifin
$209.22

1.61 (0.78%)

12/17/19
12/17/19
UPGRADE

BofA ups Eaton, Parker-Hannifin, Colfax, Rexnord in Multi-Industry shuffle
As previously reported, BofA/Merrill analyst Andrew Obin upgraded Eaton (ETN), Parker-Hannifin (PH) and Colfax (CFX), all to Buy from Neutral, and double upgraded Rexnord (RXN) to Buy from Underperform as he shuffled his ratings in the Multi-Industry sector. The impacts of tariffs, trade tensions, and decelerating global industrial production should fade in 2020, while the United States-Mexico-Canada Agreement will clear the way for possible reshoring of supply chains to North America, contends Obin. His changes in sector ratings reflects a bias towards stocks with cyclical EPS recovery potential and "strong execution," the analyst added.
12/17/19
STFL
12/17/19
UPGRADE
Target $229
STFL
Buy
Parker-Hannifin upgraded to Buy from Hold at Stifel
Stifel analyst Nathan Jones upgraded Parker-Hannifin to Buy from Hold with a price target of $229, up from $199. After the company cut its fiscal 2020 outlook heavily on the Q3 earnings call, the current outlook is "de-risked," Jones tells investors in a research note. Current macro trends indicate that we are about in the middle of what looks to be a "very shallow" industrial recession, says the analyst, who expects the industrial economy to return to growth in Q2 of 2020. Further, with recent positive developments on trade, Jones thinks investors can focus on the industry recovery, some inventory restocking, and Parker-Hannifin's synergies and growth from recent acquisitions.
12/16/19
WELS
12/16/19
UPGRADE
Target $230
WELS
Overweight
Parker-Hannifin upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo analyst Andrew Casey upgraded Parker-Hannifin to Overweight from Equal Weight with a price target of $230, up from $205. The company's current fiscal 2020 guidance "appears to limit downside risk," Casey tells investors in a research note. U.S. and international industrial short-cycle demand may be bottoming with trend improvement over the next four quarters against progressively easier year earlier comparisons and dissipating channel destocking, adds the analyst. Further, Casey sees ongoing internal return improvement initiatives plus decreasing cost headwinds amplifying Parker-Hannifin's earnings response to revenue recovery.
12/17/19
BOFA
12/17/19
UPGRADE
BOFA
Buy
Parker-Hannifin upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Andrew Obin upgraded Parker-Hannifin to Buy from Neutral.
VRA Vera Bradley
$11.53

0.45 (4.06%)

12/17/19
COWN
12/17/19
UPGRADE
Target $14
COWN
Outperform
Vera Bradley upgraded to Outperform from Market Perform at Cowen
Cowen analyst Oliver Chen upgraded Vera Bradley to Outperform from Market Perform with a $14 price target.
12/17/19
COWN
12/17/19
UPGRADE
Target $14
COWN
Outperform
Vera Bradley upgraded to Outperform at Cowen
Cowen analyst Oliver Chen upgraded Vera Bradley to Outperform from Market Perform as he believes performance and "hands free" driven product innovation will drive consistent comps. The analyst also modeled its acquisition of Pura Vida to contribute meaningful earnings per share growth of +20%. Chen raised his price target to $14 from $12 on Vera Bradley shares.
JNJ Johnson & Johnson
$142.64

0.88 (0.62%)

12/17/19
MSCO
12/17/19
UPGRADE
Target $170
MSCO
Overweight
Morgan Stanley sees 'defensiveness returning' at J&J, upgrades to Overweight
As previously reported, Morgan Stanley analyst David Lewis upgraded Johnson & Johnson to Overweight from Equal Weight with a price target of $170, up from $145. Pharma growth is likely to accelerate in 2020, which historically has lifted the stock's multiple, while its Consumer segment is stabilizing and the Medical Devices & Diagnostics unit has seen "six consecutive quarters of momentum improvement," Lewis tells investors. The stock also appears to be pricing in "significantly more legal liability" than he sees as probable, Lewis added. The analyst sees J&J's "defensiveness returning," which he thinks can lead to outperformance in 2020.
12/17/19
MSCO
12/17/19
UPGRADE
Target $170
MSCO
Overweight
Johnson & Johnson upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lewis upgraded Johnson & Johnson to Overweight from Equal Weight with a $170 price target.
12/11/19
PIPR
12/11/19
NO CHANGE
Target $28
PIPR
Overweight
XBiotech price target raised to $28 from $16 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro raised his price target for XBiotech (XBIT) to $28 from $16 after fully incorporating the sale of bermekimab to Johnson & Johnson (JNJ) into his model. XBiotech now has "runway sufficient" to fully explore the role of IL-1alpha across numerous non-derm indications as well as its True Human Antibody discovery platform, Catanzaro tells investors in a research note. He keeps an Overweight rating on the shares.
12/09/19
STFL
12/09/19
NO CHANGE
Target $96
STFL
Hold
Bluebird Bio share rebound potential dampened by JNJ-4528 news, says Stifel
Stifel analyst Benjamin Burnett said the bb2121 KarMMa data reported by Bluebird Bio (BLUE) "looks approvable" and likely will lead to Bluebird having a first mover advantage in multiple myeloma. However, although he sees Bluebird as "clearly ahead of competitors," he thinks it will be tough for the stock to appreciate beyond a small rebound given there are "so many me-too programs advancing behind them," including Janssen's (JNJ) JNJ-4528, which generated "high ORR." Burnett, who keeps a Hold rating and $96 price target on Bluebird shares, added that LentiGlobin continues to look impressive in sickle cell disease, but that disease area "has become a hotbed for gene therapy/gene editing development."

TODAY'S FREE FLY STORIES

FB

Facebook

$222.01

0.23 (0.10%)

16:50
01/19/20
01/19
16:50
01/19/20
16:50
Periodicals
Facebook blames technical error for vulgar translation, Reuters reports »

Facebook blamed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:43
01/19/20
01/19
16:43
01/19/20
16:43
Periodicals
China to increase U.S. imports according to 'market principles,' Reuters reports »

China will negotiate with…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:33
01/19/20
01/19
16:33
01/19/20
16:33
Periodicals
Tesla closer to opening first European factory with property deal, Reuters says »

Tesla has agreed to buy a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

JPM

JPMorgan

$138.15

0.89 (0.65%)

, BNPQY

BNP Paribas

$0.00

(0.00%)

16:28
01/19/20
01/19
16:28
01/19/20
16:28
Periodicals
JPMorgan to acquire former BNP building in Paris, Bloomberg reports »

JPMorgan (JPM) is buying…

JPM

JPMorgan

$138.15

0.89 (0.65%)

BNPQY

BNP Paribas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 25

    Feb

  • 14

    Apr

BAC

Bank of America

$34.70

-0.03 (-0.09%)

16:25
01/19/20
01/19
16:25
01/19/20
16:25
Periodicals
CEO tells FT Bank of America aims to 'double' slice of U.S. retail business »

Bank of America can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 15

    Apr

CEL

Cellcom Israel

$3.18

(0.00%)

16:16
01/19/20
01/19
16:16
01/19/20
16:16
Hot Stocks
Cellcom Israel announces CTO resignation »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

$15.94

0.21 (1.34%)

16:12
01/19/20
01/19
16:12
01/19/20
16:12
Hot Stocks
Verrica announces presentation of data from Phase 3 CAMP trials of VP-102 »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

SO

Southern Company

$67.25

1.08 (1.63%)

, XEL

Xcel Energy

$65.38

0.34 (0.52%)

16:08
01/19/20
01/19
16:08
01/19/20
16:08
Hot Stocks
Southern Power closes sale of Mankato Energy Center to Xcel Energy »

Southern Power, a…

SO

Southern Company

$67.25

1.08 (1.63%)

XEL

Xcel Energy

$65.38

0.34 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.